Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01257698 · ClinicalTrials.gov registry record · NA
Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy
A NA study, sponsored by Mid Atlantic Retina.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT01257698 is a NA study that has completed, run by Mid Atlantic Retina. The registered enrollment target is 21 participants.
The verdict
NCT01257698, a NA study, has completed, sponsored by Mid Atlantic Retina.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to see if glaucoma eye drops (dorzolamide-timolol) have any effect on the duration of an intraocular gas bubble following pars plana vitrectomy.
Interventions
- DRUG Dorzolamide 2%-timolol 0.5% topical eyedrops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01257698
The ClinicalTrials.gov registry entry for NCT01257698 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mid Atlantic Retina, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dorzolamide 2%-timolol 0.5% topical eyedrops is the first listed.
NCT01257698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01257698 about?
NCT01257698 is a clinical study titled "Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy". The purpose of this study is to see if glaucoma eye drops (dorzolamide-timolol) have any effect on the duration of an intraocular gas bubble following pars plana vitrectomy.
What is the current status of trial NCT01257698?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2010-02. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01257698?
The interventions under investigation include: Dorzolamide 2%-timolol 0.5% topical eyedrops (DRUG).
Who is sponsoring clinical trial NCT01257698?
This trial is sponsored by Mid Atlantic Retina, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.